Sheppard Maria K
Queen Mary University of London, London, UK.
Eur J Health Law. 2013 Jun;20(3):295-314. doi: 10.1163/15718093-12341281.
The patient mobility case law of the Court of Justice of the European Union created legal uncertainty for the healthcare systems of EU Member States. The Patient Mobility Directive setting out patients' cross-border rights was adopted to end this uncertainty. With the Directive to be transposed into national law by October 2013 this article discusses whether the Directive achieves this objective for the English NHS. It contrasts the legal position of the NHS patient under case law and under the Directive regarding the need for prior authorisation of cross-border treatment, the level of reimbursement and the ambit of the healthcare benefits basket. It is argued that the risk of legal challenge may persist under the Directive, specifically regarding treatments which are classified by health authorities as low priority, namely treatments which are either not 'generally' available or only available subject to certain clinical criteria or access thresholds.
欧盟法院关于患者流动的判例法给欧盟成员国的医疗保健系统带来了法律上的不确定性。为消除这种不确定性，欧盟通过了一项规定患者跨境权利的《患者流动指令》。鉴于该指令将于2013年10月转化为各国国内法，本文探讨了该指令是否能为英国国民医疗服务体系（NHS）实现这一目标。文章对比了在判例法以及该指令下，NHS患者在跨境治疗事先授权要求、报销水平和医疗福利范围方面的法律地位。有人认为，根据该指令，法律挑战的风险可能依然存在，尤其是对于那些被卫生当局列为低优先级的治疗，即那些要么“一般”无法获得，要么仅在满足某些临床标准或准入门槛的情况下才能获得的治疗。
